Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DDXH71
|
|||
| Drug Name |
LMP744
|
|||
| Synonyms |
LMP-744; 308246-52-8; MJ-III-65; LMP744 free base; UNII-29BY7HQV0T; NSC-706744; 29BY7HQV0T; NCI60_037977; CHEMBL126159; 308246-52-8 (free base); 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-5H-[1,3]dioxolo[4',5':5,6]indeno[1,2-c]isoquinoline-5,12(6H)-dione; AC1L9FIC; SCHEMBL4162998; DTXSID30327954; BCP34017; EX-A3021; BDBM50237809; HY-U00248; NSC706743; CS-7432; NSC-706743; Q27894415; 20-[3-(2-Hydroxyethylamino)propyl]-15,16-dimethoxy-5,7-dioxa-20-azapentacyclo[10.8.0.02,10.04,8.013,18]icosa-1(12),2,4(8),9,13,15,17-heptaene-11,19-dione; 5H-(1,3)Dioxolo(5,6)indeno(1,2-C)isoquinoline-5,12(6H)-dione, 6-(3-((2-hydroxyethyl)amino)propyl)-2,3-dimethoxy-; 5H-[1,6]indeno[1,2-c]isoquinoline- 5,12(6H)-dione,6-[3-[(2-hydroxyethyl)amino]propyl]-2,3-dimethoxy-; 6-[3-(2-Hydroxyethyl)aminopropyl]-5,11-diketo-2,3-dimethoxy-8,9-(methylenedioxy)- 11H-indeno[1,2-c]isoquinoline
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
Gibson Oncology
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H24N2O7
|
|||
| Canonical SMILES |
COC1=C(C=C2C(=C1)C3=C(C4=CC5=C(C=C4C3=O)OCO5)N(C2=O)CCCNCCO)OC
|
|||
| InChI |
1S/C24H24N2O7/c1-30-17-8-13-16(11-18(17)31-2)24(29)26(6-3-4-25-5-7-27)22-14-9-19-20(33-12-32-19)10-15(14)23(28)21(13)22/h8-11,25,27H,3-7,12H2,1-2H3
|
|||
| InChIKey |
QCSDJDQOJBQTDV-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 308246-52-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DNA topoisomerase I (TOP1) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | DNA replication | |||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | |||
| WikiPathways | Integrated Pancreatic Cancer Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03030417) Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas. U.S. National Institutes of Health. | |||
| REF 2 | Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.